NewAmsterdam Pharma Company NAMS Increase Decrease In Prepayments And Other Receivables
Increase Decrease In Prepayments And Other Receivables at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept nams:IncreaseDecreaseInPrepaymentsAndOtherReceivables.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's increase decrease in prepayments and other receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's increase decrease in prepayments and other receivables?
- NewAmsterdam Pharma Company (NAMS) reported increase decrease in prepayments and other receivables of -$15.22M in Q1 2026.
- How has NewAmsterdam Pharma Company's increase decrease in prepayments and other receivables changed year-over-year?
- NewAmsterdam Pharma Company's increase decrease in prepayments and other receivables increased by 5.1% year-over-year, from -$16.03M to -$15.22M.
- What is the long-term trend for NewAmsterdam Pharma Company's increase decrease in prepayments and other receivables?
- Over 2 years (2021 to 2024), NewAmsterdam Pharma Company's increase decrease in prepayments and other receivables has grown at a 82.7% compound annual growth rate (CAGR), from $5.23M to $17.46M.
- What does increase decrease in prepayments and other receivables mean?
- This metric tracks the net change in prepayments and other receivables, indicating how much cash is tied up in advance payments or amounts owed to the company. An increase represents a use of cash, while a decrease represents a source of cash. It provides insight into the company's working capital management and short-term liquidity efficiency.